530 related articles for article (PubMed ID: 19447220)
1. Down-regulation of the HGF/MET autocrine loop induced by celecoxib and mediated by P-gp in MDR-positive human hepatocellular carcinoma cell line.
Mazzanti R; Platini F; Bottini C; Fantappiè O; Solazzo M; Tessitore L
Biochem Pharmacol; 2009 Jul; 78(1):21-32. PubMed ID: 19447220
[TBL] [Abstract][Full Text] [Related]
2. P-glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines.
Fantappiè O; Solazzo M; Lasagna N; Platini F; Tessitore L; Mazzanti R
Cancer Res; 2007 May; 67(10):4915-23. PubMed ID: 17510421
[TBL] [Abstract][Full Text] [Related]
3. Id1 is down-regulated by hepatocyte growth factor via ERK-dependent and ERK-independent signaling pathways, leading to increased expression of p16INK4a in hepatoma cells.
Ushio K; Hashimoto T; Kitamura N; Tanaka T
Mol Cancer Res; 2009 Jul; 7(7):1179-88. PubMed ID: 19567783
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells.
Cui W; Yu CH; Hu KQ
Clin Cancer Res; 2005 Nov; 11(22):8213-21. PubMed ID: 16299255
[TBL] [Abstract][Full Text] [Related]
6. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
[TBL] [Abstract][Full Text] [Related]
7. Hepatocyte growth factor and inducible nitric oxide synthase are involved in multidrug resistance-induced angiogenesis in hepatocellular carcinoma cell lines.
Lasagna N; Fantappiè O; Solazzo M; Morbidelli L; Marchetti S; Cipriani G; Ziche M; Mazzanti R
Cancer Res; 2006 Mar; 66(5):2673-82. PubMed ID: 16510587
[TBL] [Abstract][Full Text] [Related]
8. Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib.
Xie H; Gao L; Chai N; Song J; Wang J; Song Z; Chen C; Pan Y; Zhao L; Sun S; Wu K; Feitelson MA; Liu J; Fan D
Mol Carcinog; 2009 Jan; 48(1):56-65. PubMed ID: 18506760
[TBL] [Abstract][Full Text] [Related]
9. Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt.
Liu B; Shi ZL; Feng J; Tao HM
Cell Biol Int; 2008 May; 32(5):494-501. PubMed ID: 18078766
[TBL] [Abstract][Full Text] [Related]
10. A chenodeoxycholic derivative, HS-1200, induces apoptosis and cell cycle modulation via Egr-1 gene expression control on human hepatoma cells.
Park SE; Lee SW; Hossain MA; Kim MY; Kim MN; Ahn EY; Park YC; Suh H; Kim GY; Choi YH; Kim ND
Cancer Lett; 2008 Oct; 270(1):77-86. PubMed ID: 18554781
[TBL] [Abstract][Full Text] [Related]
11. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1.
Arunasree KM; Roy KR; Anilkumar K; Aparna A; Reddy GV; Reddanna P
Leuk Res; 2008 Jun; 32(6):855-64. PubMed ID: 18083230
[TBL] [Abstract][Full Text] [Related]
12. Leptin induces proliferation and anti-apoptosis in human hepatocarcinoma cells by up-regulating cyclin D1 and down-regulating Bax via a Janus kinase 2-linked pathway.
Chen C; Chang YC; Liu CL; Liu TP; Chang KJ; Guo IC
Endocr Relat Cancer; 2007 Jun; 14(2):513-29. PubMed ID: 17639064
[TBL] [Abstract][Full Text] [Related]
13. Attenuation of transforming growth factor beta-induced growth inhibition in human hepatocellular carcinoma cell lines by cyclin D1 overexpression.
Jong HS; Lee HS; Kim TY; Im YH; Park JW; Kim NK; Bang YJ
Biochem Biophys Res Commun; 2002 Mar; 292(2):383-9. PubMed ID: 11906173
[TBL] [Abstract][Full Text] [Related]
14. Expression of CD147 mediates tumor cells invasion and multidrug resistance in hepatocellular carcinoma.
Jia L; Xu H; Zhao Y; Jiang L; Yu J; Zhang J
Cancer Invest; 2008 Dec; 26(10):977-83. PubMed ID: 19093255
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells.
Maier TJ; Schilling K; Schmidt R; Geisslinger G; Grösch S
Biochem Pharmacol; 2004 Apr; 67(8):1469-78. PubMed ID: 15041464
[TBL] [Abstract][Full Text] [Related]
16. Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma.
Kern MA; Haugg AM; Koch AF; Schilling T; Breuhahn K; Walczak H; Fleischer B; Trautwein C; Michalski C; Schulze-Bergkamen H; Friess H; Stremmel W; Krammer PH; Schirmacher P; Müller M
Cancer Res; 2006 Jul; 66(14):7059-66. PubMed ID: 16849551
[TBL] [Abstract][Full Text] [Related]
17. Parthenolide cooperates with NS398 to inhibit growth of human hepatocellular carcinoma cells through effects on apoptosis and G0-G1 cell cycle arrest.
Ralstin MC; Gage EA; Yip-Schneider MT; Klein PJ; Wiebke EA; Schmidt CM
Mol Cancer Res; 2006 Jun; 4(6):387-99. PubMed ID: 16778086
[TBL] [Abstract][Full Text] [Related]
18. Cantharidin reverses multidrug resistance of human hepatoma HepG2/ADM cells via down-regulation of P-glycoprotein expression.
Zheng LH; Bao YL; Wu Y; Yu CL; Meng X; Li YX
Cancer Lett; 2008 Dec; 272(1):102-9. PubMed ID: 18703276
[TBL] [Abstract][Full Text] [Related]
19. Different levels of p53 induced either apoptosis or cell cycle arrest in a doxycycline-regulated hepatocellular carcinoma cell line in vitro.
Lai PB; Chi TY; Chen GG
Apoptosis; 2007 Feb; 12(2):387-93. PubMed ID: 17191126
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels.
Baiz D; Pozzato G; Dapas B; Farra R; Scaggiante B; Grassi M; Uxa L; Giansante C; Zennaro C; Guarnieri G; Grassi G
Biochimie; 2009 Mar; 91(3):373-82. PubMed ID: 19041685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
